Get the Stockscreener App
3.79
0.52%
-0.02
After Hours:
3.83
0.04
+1.06%
Precigen Inc stock is traded at $3.79, with a volume of 3.20M.
It is down -0.52% in the last 24 hours and down -19.87% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$3.81
Open:
$3.71
24h Volume:
3.20M
Relative Volume:
0.73
Market Cap:
$1.34B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-9.7179
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-13.47%
1M Performance:
-19.87%
6M Performance:
-17.43%
1Y Performance:
+116.57%
1-Day Range:
$3.70
$3.95
1-Week Range:
$3.63
$4.42
52-Week Range:
$1.11
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.79 | 1.35B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Aug Update: Can Precigen Inc beat the S P 5002025 Winners & Losers & Safe Capital Growth Tips - baoquankhu1.vn
Precigen, Inc. Hits Day Low of $4.04 Amid Price Pressure - Markets Mojo
Precigen, Inc. Experiences Evaluation Revision Amidst Mixed Market Performance Indicators - Markets Mojo
Precigen, Inc. (PGEN): Investor Outlook On A Biotech With 88% Potential Upside - DirectorsTalk Interviews
Why analysts remain bullish on Precigen Inc. stockMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru
Key Takeaways - StocksToTrade
Precigen (NASDAQ:PGEN) Shares Down 6%What's Next? - MarketBeat
Strategic Moves Boost PGEN Momentum Amidst Market Shifts - StocksToTrade
Precigen (NASDAQ:PGEN) Hits New 12-Month HighHere's What Happened - MarketBeat
Can Precigen Translate PAPZIMEOS Momentum Into Revenue Growth And Shareholder Gains? - RTTNews
Precigen (NASDAQ:PGEN) Trading 5.2% HigherStill a Buy? - MarketBeat
Precigen stock hits 52-week high at 5.23 USD - Investing.com
Commit To Buy Precigen At $4, Earn 26.2% Using Options - Nasdaq
Precigen stock hits 52-week high at 5.23 USD By Investing.com - Investing.com UK
3 High Growth Companies With Strong Insider Ownership - simplywall.st
Will Precigen Inc. stock maintain growth story2025 Volatility Report & Daily Stock Trend Reports - mfd.ru
What are Precigen Inc.’s recent SEC filings showingJuly 2025 Update & Reliable Entry Point Trade Alerts - mfd.ru
Macro Review: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Fed Impact & Verified Chart Pattern Signals - baoquankhu1.vn
Why Precigen Inc. stock remains on watchlistsJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - mfd.ru
Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support - Finviz
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Promising 79% Upside Potential in Biotechnology - DirectorsTalk Interviews
Goldman Sachs Penny Stocks: Top 12 Stock Picks - Insider Monkey
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Standard Of Care Endorsement - Sahm
Gains Recap: Is Planet Labs PBC stock a buy or sell2025 Market Outlook & Daily Growth Stock Tips - baoquankhu1.vn
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech (NASDAQ:PGEN) - Seeking Alpha
What are Precigen Inc.’s growth levers2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Risk Hedge: What is the dividend yield of Precigen IncJuly 2025 Closing Moves & Weekly Top Gainers Trade List - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: Unpacking The 100% Upside Potential - DirectorsTalk Interviews
Market Trends: Is Precigen Inc stock risky to hold nowTrade Ideas & Community Shared Stock Ideas - baoquankhu1.vn
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy - simplywall.st
AI Stocks: Can Bioceres Crop Solutions Corp outperform under higher oil pricesMarket Trend Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: 87% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th - Nasdaq
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Potential 75% Upside in the Biotech Sector - DirectorsTalk Interviews
Market Pulse: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next - simplywall.st
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN - MarketBeat
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - Finviz
New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest - MarketBeat
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - Sahm
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):